NEW YORK (
CHANGE IN RATINGS
(GRPN - Get Report)
upgraded at Morgan Stanley from Equal-weight to Overweight, Morgan Stanley said. $14 price target. Company can expand its domestic turnaround into the international market.
upgraded at Citi from Neutral to Buy, Citigroup said. $67 price target. Fears of a Liberty tender have been overblown.
upgraded at DA Davidson from Neutral to Buy, DA Davidson said. $20 price target. Ainsworth transaction should add to earnings.
rated new Hold at Keybanc. Company has a new management team, which still needs to prove its worth to investors.
upgraded at Lazard from Neutral to Buy, Lazard Capital Markets said. $78 price target. Stock is attractive, following a 12% pullback.
downgraded at Morgan Stanley from Equal-weight to Underweight, Morgan Stanley said. Valuation call, based on a $60 price target.
upgraded at Credit Suisse from Neutral to Outperform, Credit Suisse said. $60 price target. Stock appears washed out at current levels.
rated new Outperform at Baird. $36 price target. Company is addressing expanding global demand for mobile automation.
(Z - Get Report)
downgraded at Morgan Stanley from Equal-weight to Underweight, Morgan Stanley said. $70 price target. Have concerns about saturation of the total addressable market.
STOCK COMMENTS / EPS CHANGES
(BRCM - Get Report)
numbers cut at Jefferies. Shares of BRCM now seen reaching $34, Jefferies said. Estimates also lowered on higher OpEx associated with Renesas acquisition. Buy rating.
Broadcom estimates, target cut at BMO. Shares of BRCM now seen reaching $27, according to BMO Capital. Estimates also reduced, as the Renesas acquisition could cut into earnings. Market Perform rating.
(CIEN - Get Report)
estimates, target raised at UBS. Shares of CIEN now seen reaching $24, according to UBS. Estimates also increased, given the strong spending cycle. Neutral rating.
(DG - Get Report)
numbers increased at BMO. DG estimates were raised through 2014, BMO Capital said. Company is seeing higher same-store sales growth. Outperform rating and new $69 price target.
price target increased at JPMorgan to $110, JPMorgan said. Risk/reward remains compelling and Medicare Advantage sentiment has improved. Overweight rating.
estimates, target boosted at Credit Suisse. Shares of VRNT now seen reaching $38, according to Credit Suisse. Estimates also upped, given solid sales execution and market share gains. Neutral rating.
>To submit a news tip, email:
and become a fan on